Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Beam Therapeutics (BEAM) Enterprise Value (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Enterprise Value for 7 consecutive years, with -$1.2 billion as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 46.37% to -$1.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$1.2 billion through Dec 2025, down 46.37% year-over-year, with the annual reading at -$1.2 billion for FY2025, 46.37% down from the prior year.
  • Enterprise Value for Q4 2025 was -$1.2 billion at Beam Therapeutics, down from -$1.1 billion in the prior quarter.
  • The five-year high for Enterprise Value was -$156.5 million in Q3 2022, with the low at -$1.2 billion in Q4 2025.
  • Average Enterprise Value over 5 years is -$865.8 million, with a median of -$1.0 billion recorded in 2023.
  • The sharpest move saw Enterprise Value soared 83.23% in 2022, then plummeted 548.81% in 2023.
  • Over 5 years, Enterprise Value stood at -$560.0 million in 2021, then tumbled by 92.53% to -$1.1 billion in 2022, then decreased by 10.36% to -$1.2 billion in 2023, then increased by 28.5% to -$850.7 million in 2024, then crashed by 46.37% to -$1.2 billion in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$1.2 billion, -$1.1 billion, and -$1.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.